Literature DB >> 16934037

Analyses of co-operative transitions in Plasmodium falciparum beta-ketoacyl acyl carrier protein reductase upon co-factor and acyl carrier protein binding.

Krishanpal Karmodiya1, Namita Surolia.   

Abstract

The type II fatty acid synthase pathway of Plasmodium falciparum is a validated unique target for developing novel antimalarials because of its intrinsic differences from the type I pathway operating in humans. beta-Ketoacyl-acyl carrier protein reductase is the only enzyme of this pathway that has no isoforms and thus selective inhibitors can be developed for this player of the pathway. We report here intensive studies on the direct interactions of Plasmodiumbeta-ketoacyl-acyl carrier protein reductase with its cofactor, NADPH, acyl carrier protein, acetoacetyl-coenzyme A and other ligands in solution, by monitoring the intrinsic fluorescence (lambdamax 334 nM) of the protein as a result of its lone tryptophan, as well as the fluorescence of NADPH (lambdamax 450 nM) upon binding to the enzyme. Binding of the reduced cofactor makes the enzyme catalytically efficient, as it increases the binding affinity of the substrate, acetoacetyl-coenzyme A, by 16-fold. The binding affinity of acyl carrier protein to the enzyme also increases by approximately threefold upon NADPH binding. Plasmodiumbeta-ketoacyl-acyl carrier protein reductase exhibits negative, homotropic co-operative binding for NADPH, which is enhanced in the presence of acyl carrier protein. Acyl carrier protein increases the accessibility of NADPH to beta-ketoacyl-acyl carrier protein reductase, as evident from the increase in the accessibility of the tryptophan of beta-ketoacyl-acyl carrier protein reductase to acrylamide, from 81 to 98%. In the presence of NADP+, the reaction proceeds in the reverse direction (Ka=23.17 microM-1). These findings provide impetus for exploring the influence of ligands on the structure-activity relationship of Plasmodiumbeta-ketoacyl-acyl carrier protein reductase.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16934037     DOI: 10.1111/j.1742-4658.2006.05412.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  6 in total

1.  Structure of a short-chain dehydrogenase/reductase from Bacillus anthracis.

Authors:  Jing Hou; Kamila Wojciechowska; Heping Zheng; Maksymilian Chruszcz; David R Cooper; Marcin Cymborowski; Tatiana Skarina; Elena Gordon; Haibin Luo; Alexei Savchenko; Wladek Minor
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2012-05-24

2.  FabG can function as PhaB for poly-3-hydroxybutyrate biosynthesis in photosynthetic cyanobacteria Synechocystis sp. PCC 6803.

Authors:  Haowei Zhang; Yinghui Liu; Changhong Yao; Xupeng Cao; Jing Tian; Song Xue
Journal:  Bioengineered       Date:  2017-05-19       Impact factor: 3.269

3.  Mass spectrometry-based systems approach for identification of inhibitors of Plasmodium falciparum fatty acid synthase.

Authors:  Shilpi Sharma; Shailendra Kumar Sharma; Rahul Modak; Krishanpal Karmodiya; Namita Surolia; Avadhesha Surolia
Journal:  Antimicrob Agents Chemother       Date:  2007-05-07       Impact factor: 5.191

4.  Dissecting the Structural Elements for the Activation of β-Ketoacyl-(Acyl Carrier Protein) Reductase from Vibrio cholerae.

Authors:  Jing Hou; Heping Zheng; Maksymilian Chruszcz; Matthew D Zimmerman; Igor A Shumilin; Tomasz Osinski; Matt Demas; Sarah Grimshaw; Wladek Minor
Journal:  J Bacteriol       Date:  2015-11-09       Impact factor: 3.490

5.  Role of Serine140 in the mode of action of Mycobacterium tuberculosis β-ketoacyl-ACP Reductase (MabA).

Authors:  Leonardo A Rosado; Rafael Andrade Caceres; Walter Filgueira de Azevedo; Luiz A Basso; Diógenes S Santos
Journal:  BMC Res Notes       Date:  2012-09-25

6.  Merozoite Proteins Discovered by qRT-PCR-Based Transcriptome Screening of Plasmodium falciparum.

Authors:  Nan Hou; Shanshan Li; Ning Jiang; Xianyu Piao; Yu Ma; Shuai Liu; Qijun Chen
Journal:  Front Cell Infect Microbiol       Date:  2021-12-09       Impact factor: 5.293

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.